Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety

Fineline Cube Feb 18, 2025

In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...

Company Drug

Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS

Fineline Cube Feb 18, 2025

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) announced that its mecobalamin product has...

Company Drug

Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC

Fineline Cube Feb 18, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn...

Company Drug

AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans

Fineline Cube Feb 18, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...

Company Deals

Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market

Fineline Cube Feb 18, 2025

China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...

Company Drug

Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study

Fineline Cube Feb 18, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...

Company Deals

PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development

Fineline Cube Feb 18, 2025

PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...

Company Drug

Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars

Fineline Cube Feb 17, 2025

South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...

Company Drug

Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections

Fineline Cube Feb 17, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...

Company Drug

Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment

Fineline Cube Feb 17, 2025

The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...

Company Deals

Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study

Fineline Cube Feb 17, 2025

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...

Company Drug

GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25

Fineline Cube Feb 17, 2025

UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...

Company Deals

3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China

Fineline Cube Feb 17, 2025

China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...

Company Drug

LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites

Fineline Cube Feb 17, 2025

Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...

Company Drug

IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma

Fineline Cube Feb 17, 2025

China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...

Company Drug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Fineline Cube Feb 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...

Company Deals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Fineline Cube Feb 17, 2025

Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...

Company Drug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Fineline Cube Feb 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...

Company Drug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Fineline Cube Feb 17, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...

Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Fineline Cube Feb 16, 2025

In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...

Posts pagination

1 … 256 257 258 … 710

Recent updates

  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
  • Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.